PolyPid (PYPD) awards director 9,132 stock options at $4.46
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Stein Robert Benjamin reported acquisition or exercise transactions in this Form 4 filing.
PolyPid Ltd. director Robert Benjamin Stein received a grant of 9,132 stock options to purchase Ordinary Shares at $4.46 per share. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030 and expire on July 15, 2036. Following this grant, he holds 9,132 options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Stein Robert Benjamin
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 9,132 | $4.46 | $41K |
Holdings After Transaction:
Stock option (right to buy) — 9,132 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 9,132 options
Exercise price: $4.46 per share
Underlying shares: 9,132 Ordinary Shares
+3 more
6 metrics
Stock options granted
9,132 options
Stock option grant on July 15, 2026 to director Robert Benjamin Stein
Exercise price
$4.46 per share
Conversion or exercise price for the 9,132 stock options
Underlying shares
9,132 Ordinary Shares
Each option is exercisable into one Ordinary Share
Expiration date
July 15, 2036
Expiration date of the granted stock options
Vesting period end
April 15, 2030
Options vest on a quarterly basis until April 15, 2030
Options held after grant
9,132 options
Total derivative securities beneficially owned following the transaction
Key Terms
Stock option (right to buy), conversion or exercise price, expiration date, Ordinary Shares, +1 more
5 terms
Stock option (right to buy) financial
"Security title is listed as "Stock option (right to buy)" for the transaction"
conversion or exercise price financial
"The conversion or exercise price for the options is reported as $4.4600"
expiration date financial
"The expiration date for the stock option grant is July 15, 2036"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest on a quarterly basis financial
"The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did PolyPid (PYPD) report for Robert Benjamin Stein?
PolyPid reported that director Robert Benjamin Stein was granted 9,132 stock options on July 15, 2026 at an exercise price of $4.46 per share. Each option is exercisable into one Ordinary Share, increasing his directly held option position to 9,132 options.
What is the exercise price of the new PolyPid (PYPD) stock options granted to Robert Benjamin Stein?
The new stock options for Robert Benjamin Stein carry an exercise price of $4.46 per share. This price applies to all 9,132 options, each of which is exercisable into one Ordinary Share if and when the options are vested and exercised.
How do the 9,132 PolyPid (PYPD) stock options granted to Robert Benjamin Stein vest?
The 9,132 options granted to Robert Benjamin Stein vest on a quarterly basis beginning July 15, 2026. Vesting continues through April 15, 2030, meaning portions of the award become exercisable over this multi‑year period rather than all at once.
When do Robert Benjamin Stein’s PolyPid (PYPD) stock options expire?
The stock options granted to Robert Benjamin Stein expire on July 15, 2036 if not exercised. After this expiration date, any unexercised options from this 9,132‑unit grant will no longer be exercisable into PolyPid Ordinary Shares.
How many PolyPid (PYPD) options does Robert Benjamin Stein hold after this grant?
Following the reported grant, Robert Benjamin Stein beneficially owns 9,132 stock options directly. This total reflects the entire new award, as indicated by the post‑transaction holdings figure for derivative securities in the insider transaction report.
Was Robert Benjamin Stein’s PolyPid (PYPD) option grant made under a Rule 10b5-1 trading plan?
The report indicates the transaction was not affirmed as made under a Rule 10b5-1 plan, as the related checkbox is marked false. The disclosure instead classifies the event as a grant or award acquisition of derivative securities.